A total of 224 cancer patients receiving PD-1/PD-L1 inhibitor treatment were included in this study, consisting of 112 in the risk-antibody group (87 high-risk, 20 intermediate-risk, and 5 low-risk), 51 in the unknown-risk antibody group, and 61 in the antibody-negative group. The gene discussed is PDCD1; the disease is cancer.